Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Cassava Sciences (NASDAQ:SAVA) Shares Down 3.8% | news.google.com • |
Cassava Sciences stock gains on pact with ex-CEO (NASDAQ:SAVA) | news.google.com • |
Cassava Sciences (NASDAQ:SAVA) Trading Up 10.8% | news.google.com • |
(SAVA) Technical Pivots with Risk Controls | news.google.com • |
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference | globenewswire.com • |
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid? | marketbeat.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-05 | 2024-09 | -1.37 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | -0.44 | -1.28 | -0.84 | -190.91% |
2024-05-10 | 2024-03 | -0.51 | -1.41 | -0.9 | -176.47% |
2024-02-28 | 2023-12 | -0.4 | -0.5 | -0.1 | -25.00% |
2023-11-07 | 2023-09 | -0.9 | -0.61 | 0.29 | 32.22% |
2023-08-03 | 2023-06 | -0.58 | -0.63 | -0.05 | -8.62% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-08 | HC Wainwright & Co. | Upgrade | Buy | |
2023-03-05 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-23 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2018-10-02 | ARMISTICE CAPITAL L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2023-05-23 | BARBIER REMI | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
2024-04-22 | BARRY RICHARD J | Director | 0.00 | Conversion of Exercise of derivative security |
2022-10-02 | FRIEDMANN NADAV | Officer and Director | 80.05K | Conversion of Exercise of derivative security |
2023-04-30 | GUSSIN ROBERT Z | Director | 10.62K | Conversion of Exercise of derivative security |
2024-04-17 | KUPIEC JAMES WILLIAM | Officer | 4.00K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 2.75M | 67.35M | 6.54% |
2023-06-29 | Vanguard Group Inc | 2.25M | 55.16M | 5.36% |
2023-06-29 | State Street Corporation | 952.09K | 23.35M | 2.27% |
2023-06-29 | Geode Capital Management, LLC | 803.31K | 19.70M | 1.91% |
2023-06-29 | Gallacher Capital Management LLC | 583.29K | 14.30M | 1.39% |
2023-06-29 | Northern Trust Corporation | 370.64K | 9.09M | 0.88% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.23M | 30.21M | 2.94% |
2023-08-30 | iShares Russell 2000 ETF | 908.42K | 19.05M | 2.16% |
2023-06-29 | Vanguard Extended Market Index Fund | 542.35K | 13.30M | 1.29% |
2023-07-30 | Fidelity Small Cap Index Fund | 353.09K | 7.76M | 0.84% |
2023-08-30 | iShares Russell 2000 Growth ETF | 333.17K | 6.99M | 0.79% |
2023-05-30 | Fidelity Extended Market Index Fund | 202.34K | 4.60M | 0.48% |
Dividend | Date |
---|---|
0.75 | 2012-12-13 |
2 | 2010-12-13 |
Split | Date |
---|---|
1 : 7 | 2017-05-10 |
-
-
-
-
-
-
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
-
-
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
-
-
-
-
-
HERE IS WHAT YOU MISSED:
*A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Systematic review: Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease.
*Per the company,
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
So, BEFORE you DUMP, you may want to RECONSIDER. Neuro Inflammation is core to the onset and progression of Alzheimers. THAT aspect of the PTI-125s efficacy ALONE, makes it A BLOCKBUSTER DRUG!
-
-
Cassava Sciences (NASDAQ:SAVA) Shares Down 3.8%
news.google.com • -
Cassava Sciences stock gains on pact with ex-CEO (NASDAQ:SAVA)
news.google.com • -
Cassava Sciences (NASDAQ:SAVA) Trading Up 10.8%
news.google.com • -
(SAVA) Technical Pivots with Risk Controls
news.google.com • -
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
globenewswire.com • -
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
marketbeat.com • -
Cassava Sciences Q2 Earnings Review: So Many Questions, So Few Answers
seekingalpha.com • -
2 Biotech Stocks Making Moves Today
schaeffersresearch.com • -
Cassava Sciences News: Why Is SAVA Stock Trending Today?
investorplace.com • -
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
globenewswire.com • -
Get Your Money Out of These 3 Healthcare Stocks ASAP
investorplace.com • -
SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months
investorplace.com • -
Cassava Sciences Announces Expansion of Open-Label Extension Trials
globenewswire.com • -
Get Your Money Out of These 3 Biotech Stocks Before the End of July
investorplace.com • -
SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update
investorplace.com • -
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
investorplace.com • -
3 Healthcare Stocks to Sell in July Before They Crash & Burn
investorplace.com • -
Top 5 Health Care Stocks That May Explode In July
benzinga.com • -
3 Biotech Stocks to Sell in July Before They Crash & Burn
investorplace.com • -
Why Cassava Sciences Stock Is Sinking Today
fool.com •